Advanced Search

 

Study ID Status Title Patient Level Data
SAS30019 Completed A multicentre, randomised, double-blind, double-dummy, parallel group study to compare salmeterol/fluticasone propionate combination 50/100mcg twice daily delivered via dry powder inhaler (Diskus/Accuhaler) or non-chlorofluorocarbon metered-dose inhaler in the treatment of children with asthma aged 4-11 years. Study Listed on ClinicalStudyDataRequest.com
SAS30021 Completed A stratified, randomized, double-blind, placebo-controlled, parallel-group, 12 week trial evaluating the safety and efficacy of fluticasone propionate/salmeterol DISKUS combination product 100/50mcg once daily versus fluticasone propionate DISKUS 100mcg once daily and placebo in symptomatic pediatric subjects (4-11 years) with asthma Study Listed on ClinicalStudyDataRequest.com
SAS30022 Completed A randomized, double-blind, placebo-controlled, parallel-group, 12 week trial evaluating the safety and efficacy of the fluticasone propionate/salmeterol DISKUS combination product 250/50mcg once daily versus fluticasone propionate 250mcg once daily versus fluticasone propionate/salmeterol 100/50mcg twice daily versus placebo in symptomatic adolescent and adult subjects with asthma that is not controlled on short acting beta agonist therapy Study Listed on ClinicalStudyDataRequest.com
SAS30023 Completed A 12-week multicentre, randomised, double-blind, placebo-controlled parallel group study to compare the efficacy and tolerability of fluticasone propionate/salmeterol combination (SERETIDE/VIANI/ADVAIR) 88/42mcg once daily in the morning with fluticasone propionate 88mcg once daily in the morning and placebo (short-acting ß2-agonist as required only) once daily in the morning, all via the HFA MDI as initial maintenance therapy in mild asthmatic subjects Study Listed on ClinicalStudyDataRequest.com
SAS30024 Completed A 52-week multicentre, randomised, double-blind, double dummy, placebo-controlled parallel group study to compare the efficacy and tolerability of salmeterol/fluticasone propionate combination (SERETIDE/VIANI/ADVAIR) 50/100mcg once daily in the morning with fluticasone propionate (FLIXOTIDE/FLOV ... Study Listed on ClinicalStudyDataRequest.com
SAS30025 Completed Seretide for COntrol of REspiratory symptoms (SCORE): Switching inhaled steroids to Seretide in persistent asthma in general practice. An open label, sequential trial.
SAS30031 Completed A Randomized, Double-Blind, 12-Week Trial Evaluating the Safety of the Fluticasone Propionate/Salmeterol DISKUS Combination Product 100/50mcg twice daily Versus Fluticasone Propionate DISKUS 100mcg twice daily in Symptomatic Pediatric Subjects (4-11 Years) With Asthma Study Listed on ClinicalStudyDataRequest.com
SAS30033 Completed An Open-Label, Multi-Center Study to Evaluate the Performance and Patient Satisfaction of Fluticasone Propionate/Salmeterol HFA with Counter in Asthma or COPD Subjects at Least 12 Years of Age Study Listed on ClinicalStudyDataRequest.com
SAS30035 Completed A 52-week multi-centre, open-labelled, non-comparative study assessing the safety of salmeterol xinafoate/fluticasone propionate bid in adult patients with bronchial asthma
SAS30036 Completed A Double-Blind, Comparative Study to Compare Salmeterol/Fluticasone Propionate Combination Product (50/250mcg BID) with Concomitant Treatment with Fluticasone Propionate 250mcg BID Plus Sustained ReleaseTheophylline 200mg bid in Patients with Bronchial Asthma
SAS30038 Completed Clinical assessment of GW815SF (SLM/FP) for bronchial asthma - An open-labelled study of GW815SF (SLM/FP) 50/100mcg in patients with bronchial asthma (uncontrolled trial).
SAS30039 Completed A 12-week, multi-centre, randomised, double-blind, parallel-group study to compare the efficacy and tolerability of salmeterol/fluticasone propionate combination (SERETIDE™/VIANI™/ADVAIR™) 50/250μg twice-daily with fluticasone propionate 250μg twice-daily, all via the DISKUS®/ACCUHALER® as initial maintenance therapy in moderate persistent asthma. Study Listed on ClinicalStudyDataRequest.com
SAS30040 Completed A 12-week, randomised, double-blind, parallel-group study to compare the efficacy and tolerability ofsalmeterol/fluticasone propionate combination 50/100mcg twice daily with fluticasone propionate 250mcg twice daily, all via theDISKUS™/ACCUHALER™ on maintaining asthma control in moderate persistent asthmatic subjects whose symptomshave been well-controlled following an initial maintenance therapy with salmeterol/fluticasone propionate 50/250mcgcombination twice-daily for 12 weeks Study Listed on ClinicalStudyDataRequest.com
SAS40002 Completed A Randomised, Double-Blind, Double-Dummy, Parallel-Group Comparison of Seretide. Diskus/Accuhaler. 250/50 mg bid with Budesonide 800 mg bid plus Formoterol 12.0 mg bid (both via Breath-Actuated Dry Powder Inhaler) in Adolescent and Adult Moderate-Severe Asthmatics
SAS40006 Completed A Randomised, Double-Blind, Double-Dummy, Parallel-Group Comparison of Seretide DISKUS/ACCUHALER (50/250?g Strength) b.i.d. with Budesonide 800?g b.i.d. in Adolescents and Adults with Reversible Airways Obstruction
SAS40007 Completed A Randomised, Double-Blind, Double-Dummy, Parallel-Group Comparison of SERETIDE DISKUS/ACCUHALER (50/100?g Strength) twice daily (bid) with Budesonide 400?g bid in Adolescents and Adults with Reversible Airways Obstruction
SAS40009 Completed A multi-centre, randomised, double-blind, parallel group comparison of the salmeterol/ fluticasone propionate combination product (50/250µg) via Diskus twice daily versus fluticasone propionate (500µg) via Diskus twice daily in patients with moderate asthma (SAS 40009 local German study)
SAS40011 Completed Efficacy and Safety of salmeterol/fluticasone propionate (VIANI®) 50/250µg twice daily via Diskus in patients with mild to moderate asthma
SAS40013 Completed Can the serum level of eosinophil cationic protein (ECP) give directions for the choice between increasing the dose of fluticasone propionate or the addition of salmeterol in patients with symptomatic asthma?
SAS40014 Completed A multi-centre study examining the use of salmeterol xinafoate / fluticasone propionate via Diskus in relation to controlling asthma in moderate to severe patients: identifying risk factors contributing to an exacerbation of asthma and modification of treatment during exacerbations.
SAS40015 Completed A multicentre, randomised, double-blind, double-dummy, parallel-group, 12-week, active control comparison of the salmeterol/fluticasone propionate combination product (50/100mcg strength) bd via the DISKUS/ACCUHALERinhaler with …
SAS40018 Completed A Multi-Center, Randomized, Double-Blind, Double Dummy, Parallel-Group, 12 Week Active Control Comparison of Salmeterol/Fluticasone Propionate Combination Product (50/100mcg BID) via the DISKUS inhaler with Fluticasone Propionate (100mcg BID) via the DISKUS plus Oral Montelukast (10mg QD) in Adu ...
SAS40019 Completed A randomised, double blind, parallel group comparison of the effect of the salmeterol/fluticasone propionate combination product (50/250 mcg strength) bd via the Diskus inhaler with placebo bd via the Diskus inhaler in young adults who are in clinical remission of allergic asthma
SAS40020 Completed A Randomized, Double-Blind, Double-Dummy, Parallel Group, 12-Week Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg Twice Daily Via the DISKUS® Inhaler Versus Oral Montelukast 10mg Once Daily in Adolescents and Adults with Persistent Asthma Study Listed on ClinicalStudyDataRequest.com
SAS40021 Completed A Randomized, Double-Blind, Double-Dummy, Parallel Group, 12-Week Comparative Trial of Salmeterol/Fluticasone Propionate Combination Product 50/100mcg Twice Daily Via the DISKUS® Inhaler Versus Oral Montelukast 10mg Once Daily in Adolescents and Adults with Persistent Asthma Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.